<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ketorolac (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ketorolac (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ketorolac (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9152" href="/d/html/9152.html" rel="external">see "Ketorolac (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12236" href="/d/html/12236.html" rel="external">see "Ketorolac (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8320258"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. Oral ketorolac is only indicated as continuation treatment following IV or IM dosing of ketorolac, if necessary. The total combined duration of use of ketorolac tablets and injection should not exceed 5 days. The recommended total daily dose of ketorolac tablets (maximum 40 mg) is significantly lower than for ketorolac injection (maximum 120 mg).</p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is not indicated for use in pediatric patients and is not indicated for minor or chronic painful conditions. Increasing the dose of ketorolac beyond labeled recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular thrombotic events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is contraindicated in the setting of coronary artery bypass graft surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac is contraindicated in patients with active peptic ulcer disease, recent GI bleeding or perforation, and a history of peptic ulcer disease or GI bleeding. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intrathecal or epidural administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is contraindicated for intrathecal or epidural administration due to its alcohol content.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, ranging from bronchospasm to anaphylactic shock, have occurred and appropriate counteractive measures must be available when administering the first dose of ketorolac injection. Ketorolac is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac or allergic manifestations to aspirin or other NSAIDs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of bleeding:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, and those at high risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is contraindicated as a prophylactic analgesic before any major surgery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk during labor and delivery:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of ketorolac in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine contractions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Concomitant use with nonsteroidal anti-inflammatory drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ketorolac is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Special populations:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dosage should be adjusted for patients ≥65 years of age, for patients &lt;50 kg (110 lbs) of body weight, and for patients with moderately elevated serum creatinine. Doses of ketorolac injection are not to exceed 60 mg (total dose per day) in these patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49214910"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ReadySharp Ketorolac [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869214"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ALTI-Ketorolac;</li>
<li>APO-Ketorolac;</li>
<li>JAMP Ketorolac;</li>
<li>Mar-Ketorolac;</li>
<li>MINT-Ketorolac;</li>
<li>Toradol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10501739"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Nonopioid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antipyretic</span>;</li>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span>;</li>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462660"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b25c8913-9c08-43d0-ab3f-ac8602d744b8">Pain management, postoperative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain management (acute; moderate to severe), postoperative:</b> Limited data available: Full-term neonates PNA &gt;14 days: IV: 0.5 mg/kg/dose every 6 to 8 hours postoperatively and continued for up to 3 days generally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aldrink.2011','lexi-content-ref-11902701','lexi-content-ref-19134246','lexi-content-ref-16618297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aldrink.2011','lexi-content-ref-11902701','lexi-content-ref-19134246','lexi-content-ref-16618297'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F8349401"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> To reduce the risk of adverse cardiovascular and GI effects, use the lowest effective dose for the shortest period of time. The total duration of ketorolac (combined IV/IM and oral) should not exceed 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40f01acd-8177-4575-a113-b71120c7ad4f">Pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain management (acute; moderately severe): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: Limited data available: IV: 0.5 mg/kg/dose every 6 to 8 hours, not to exceed 48 to 72 hours of treatment; has been used postoperatively primarily following cardiac and abdominal surgery; maximum dose: 15 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7803871','lexi-content-ref-11902701','lexi-content-ref-19134246','lexi-content-ref-15365927','lexi-content-ref-16618297','lexi-content-ref-29028762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7803871','lexi-content-ref-11902701','lexi-content-ref-19134246','lexi-content-ref-15365927','lexi-content-ref-16618297','lexi-content-ref-29028762'])">Ref</a></span>). A lower dose of 0.25 mg/kg/dose every 6 to 8 hours has also been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32072099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32072099'])">Ref</a></span>). <b>Note:</b> IM administration has been described in patients ≥6 months of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents ≤16 years: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV: 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 30 mg/dose, usual reported duration: 48 to 72 hours; not to exceed 5 days of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.2016','lexi-content-ref-7803871','lexi-content-ref-11812682','lexi-content-ref-32072099','lexi-content-ref-15365927','lexi-content-ref-15675931','lexi-content-ref-29028762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.2016','lexi-content-ref-7803871','lexi-content-ref-11812682','lexi-content-ref-32072099','lexi-content-ref-15365927','lexi-content-ref-15675931','lexi-content-ref-29028762'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 1 mg/kg/dose every 4 to 6 hours; maximum dose: 10 mg/dose; maximum daily dose: 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACS.1','lexi-content-ref-9187531','lexi-content-ref-1394752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACS.1','lexi-content-ref-9187531','lexi-content-ref-1394752'])">Ref</a></span>). <b>Note: </b>Oral formulation should only be used as continuation of IV or IM therapy; do not use as initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: <b>Note:</b> The maximum combined duration of treatment (for parenteral and oral) is 5 days; do not increase dose or frequency; supplement with low-dose opioids if needed for breakthrough pain.</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">IM: 30 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 15 mg as a single dose or 15 mg every 6 hours; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Initial: 10 mg, then 10 mg every 4 to 6 hours; maximum daily dose: 40 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">IM: 60 mg as a single dose or 30 mg every 6 hours; maximum daily dose: 120 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 30 mg as a single dose or 30 mg every 6 hours; maximum daily dose: 120 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Initial: 20 mg, then 10 mg every 4 to 6 hours; maximum daily dose: 40 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114936"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are recommended for adult patients. The specific degree of renal impairment where use is permitted is not defined in the product labeling; however, use is contraindicated in patients with advanced renal impairment or those at risk for renal failure due to volume depletion; some experts have suggested the following:</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Aronoff 2007 recommendations: <b>Note:</b> Renally adjusted dose recommendations are based on doses of IV, IM: 0.25 to 1 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% to 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">KDIGO guidelines provide the following recommendations for NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F51114937"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution, may cause elevation of liver enzymes; discontinue if clinical signs and symptoms of liver disease develop.</p></div>
<div class="block doa drugH1Div" id="F8349402"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9152" href="/d/html/9152.html" rel="external">see "Ketorolac (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Consider proton pump inhibitor coadministration in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-18836135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-18836135'])">Ref</a></span>). May increase cardiovascular risk (eg, thrombotic events), particularly in patients with established cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Use the lowest effective dose for the shortest duration of time; do not shorten dosing interval of 4 to 6 hours. Patients weighing &lt;50 kg or ≥65 years of age may be at increased risk for adverse effects; lower doses are recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3251ec27-1262-44cb-9179-0a4fc9d8686d">Migraine, severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, severe, acute treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Weight ≥50 kg and &lt;65 years of age:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>: 30 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24523483','lexi-content-ref-23298250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24523483','lexi-content-ref-23298250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM</b>: 60 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23298250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23298250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Weight &lt;50 kg or </i></b>
<b>
<i>≥65 years of age:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>15 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 30 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40f01acd-8177-4575-a113-b71120c7ad4f">Pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain management, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do not exceed recommended doses or administer with another nonsteroidal anti-inflammatory drug (NSAID). May supplement with analgesic(s) from another therapeutic class for breakthrough pain. Oral formulation should not be given as initial therapy; other better tolerated oral NSAIDs are generally preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Weight ≥50 kg and &lt;65 years of age:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 30 mg as a single dose or 15 to 30 mg every 6 hours as needed; maximum daily dose: 120 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.2020','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.2020','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 30 to 60 mg as a single dose or 15 to 30 mg every 6 hours as needed; alternatively, may administer 10 to 30 mg every 4 to 6 hours as needed; maximum daily dose: 120 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mariano.2020','lexi-content-ref-Manu.1','lexi-content-ref-Canada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mariano.2020','lexi-content-ref-Manu.1','lexi-content-ref-Canada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (only as continuation of IM or IV therapy, not for initial therapy):</b> 20 mg once, followed by 10 mg every 4 to 6 hours as needed; maximum daily dose: 40 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Weight &lt;50 kg or </i></b>
<b>
<i>≥65 years of age:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 15 mg as a single dose or 15 mg every 6 hours as needed; maximum daily dose: 60 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 30 mg as a single dose or 15 mg every 6 hours as needed; alternatively, may administer 10 mg every 4 to 6 hours as needed; maximum daily dose: 60 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-Canada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-Canada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (only as continuation of IM or IV therapy, not for initial therapy): </b>10 mg every 4 to 6 hours as needed; maximum daily dose: 40 mg/day; maximum duration: 5 days combined (parenteral, oral, and nasal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991478"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>:<b> IM, IV, Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;30 to &lt;60 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> Use of analgesics other than nonsteroidal anti-inflammatory drugs may be preferred. If necessary, consider 7.5 to 15 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.2013','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.2013','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>); use the lowest effective dose for the shortest duration possible. Avoid use in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-KDIGO.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg every 4 to 6 hours as needed; maximum: 40 mg/day; oral dosing is intended to be a continuation of IM or IV therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≤30 mL/minute/1.73 m<sup>2</sup>: <b>IM, IV, Oral:</b> Avoid use due to increased risk of acute kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>). The manufacturer’s labeling states use is contraindicated in advanced kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable: <b>IM, IV, Oral: </b>Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>). The manufacturer’s labeling states use is contraindicated in advanced kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed given very high protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>IM, IV, Oral:</b> Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900801','lexi-content-ref-Expert.DOR'])">Ref</a></span>). The manufacturer’s labeling states use is contraindicated in advanced kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988822"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution to avoid adverse effects and discontinue if hepatic function worsens.</p></div>
<div class="block arsc drugH1Div" id="F58523076"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including <b>acute myocardial infarction</b> (MI), <b>cerebrovascular accident</b>, and CV death. New-onset <b>hypertension</b> or exacerbation of hypertension may occur with NSAID use, which may also contribute to an increased risk of CV events; this effect was documented following use of celecoxib, ibuprofen, or naproxen in the PRECISION-ABPM trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29020251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29020251'])">Ref</a></span>). NSAIDS should be avoided in patients hospitalized for acute coronary syndromes due to the risk of adverse cardiac events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>). New-onset or exacerbation of <b>heart failure</b> may also occur with cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs) and nonselective NSAIDs, including ketorolac, resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-26984863','lexi-content-ref-FDA.1','lexi-content-ref-30232741','lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-26984863','lexi-content-ref-FDA.1','lexi-content-ref-30232741','lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data collected by the Coxib and traditional NSAID Trialists’ Collaborative have shown that high-dose naproxen may have the most favorable CV risk profile among NSAIDs analyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23726390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23726390'])">Ref</a></span>); however, data from the PRECISION trial showed no difference with regards to risk between naproxen, ibuprofen, or celecoxib after a treatment duration of therapy of ~3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959716'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">CV risk associated with use of ketorolac was not evaluated in long-term studies as treatment with ketorolac is limited to short-term use (ie, 5 days). Additionally, several retrospective studies evaluating the use of ketorolac in patients with cardiovascular disease (CVD) undergoing coronary artery bypass graft (CABG) surgery have failed to find an increased risk of adverse effects including mortality, MI, and bleeding events in this patient population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18068059','lexi-content-ref-28970395','lexi-content-ref-24231193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18068059','lexi-content-ref-28970395','lexi-content-ref-24231193'])">Ref</a></span>); clinicians should note that these studies cannot confirm mortality benefit and/or increased graft patency. The FDA states that there are insufficient data to determine if the risk of MI or stroke is definitely higher or lower for any particular NSAID as compared to another (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I<sub>2</sub> (prostacyclin), a potent vasodilator and anticoagulant present in the vascular endothelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11509629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11509629'])">Ref</a></span>). Animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964481'])">Ref</a></span>). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; increased risk is associated with both short- and long-term use and may be apparent within the first weeks following initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28487435','lexi-content-ref-FDA.1','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28487435','lexi-content-ref-FDA.1','lexi-content-ref-21555710'])">Ref</a></span>); longer duration of therapy may further increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). Treatment with ketorolac is limited to short-term use (ie, 5 days).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥65 years of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (especially with regards to CV thrombotic risk [(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-21555710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-21555710'])">Ref</a></span>)]</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use and frequent use (eg, ≥22 days per month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16534006','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16534006','lexi-content-ref-FDA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: Treatment with ketorolac is limited to short-term use (ie, 5 days).</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting CVD, including heart failure, or presence of risk factors for CVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-24280110','lexi-content-ref-27959716','lexi-content-ref-20031832','lexi-content-ref-21555710','lexi-content-ref-25710657'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: The use of NSAIDs is contraindicated in the setting of CABG surgery due to an increased risk of MI and stroke in this patient population. Yet, retrospective studies specific to ketorolac have not shown an increased risk of death, MI, or bleeding events following use in postoperative CABG patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18068059','lexi-content-ref-28970395','lexi-content-ref-24231193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18068059','lexi-content-ref-28970395','lexi-content-ref-24231193'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially nonselective NSAIDs, such as ketorolac, is associated with an increased risk of serious gastrointestinal (GI) adverse events, including gastrointestinal inflammation, <b>gastrointestinal hemorrhage</b>, <b>gastrointestinal</b>
<b>ulcer</b>, and <b>gastrointestinal</b>
<b>perforation</b>; severity may range from asymptomatic to fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137151','lexi-content-ref-8364288','lexi-content-ref-8520083','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137151','lexi-content-ref-8364288','lexi-content-ref-8520083','lexi-content-ref-28756267','lexi-content-ref-31937550','lexi-content-ref-29667211'])">Ref</a></span>). The risk of upper GI hemorrhage and/or perforation has been reported to be higher with ketorolac as compared to other nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137151','lexi-content-ref-9437376','lexi-content-ref-9754982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137151','lexi-content-ref-9437376','lexi-content-ref-9754982'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of cyclooxygenase (COX)-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E<sub>2 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9626023','lexi-content-ref-10377455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9626023','lexi-content-ref-10377455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; GI events can occur at any time during use and without warning symptoms. A longer duration of use (eg, ≥7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9437376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9437376'])">Ref</a></span>)) is associated with a greater risk. Treatment with ketorolac is limited to short-term use (ie, 5 days).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (eg, ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (eg, ≥5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9437376','lexi-content-ref-8569017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9437376','lexi-content-ref-8569017'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note: </b>Treatment with ketorolac is limited to short-term use (ie, 5 days).</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of peptic ulcer disease and/or GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9437376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9437376'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443'])">Ref</a></span>), anticoagulants, corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20955443','lexi-content-ref-2012355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20955443','lexi-content-ref-2012355'])">Ref</a></span>), selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>))</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid <i>Helicobacter pylori </i>infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16469671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16469671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced liver disease/cirrhosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Coagulopathy</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">• Consumption of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• People with poor general health status</p>
<p style="text-indent:-2em;margin-left:6em;">• Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28052268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28052268'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including ketorolac, is associated with <b>prolonged bleeding time</b> and an increased risk for hemorrhage, particularly gastrointestinal bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aldrink.2011','lexi-content-ref-22434401','lexi-content-ref-3259170','lexi-content-ref-2082316','lexi-content-ref-8797556','lexi-content-ref-23175926','lexi-content-ref-25402512','lexi-content-ref-9422305','lexi-content-ref-11133001','lexi-content-ref-25710657','lexi-content-ref-14523887','lexi-content-ref-8569017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aldrink.2011','lexi-content-ref-22434401','lexi-content-ref-3259170','lexi-content-ref-2082316','lexi-content-ref-8797556','lexi-content-ref-23175926','lexi-content-ref-25402512','lexi-content-ref-9422305','lexi-content-ref-11133001','lexi-content-ref-25710657','lexi-content-ref-14523887','lexi-content-ref-8569017'])">Ref</a></span>). Some studies have suggested that ketorolac is not associated with increased bleeding in the perioperative period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572864','lexi-content-ref-32393370','lexi-content-ref-36892424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572864','lexi-content-ref-32393370','lexi-content-ref-36892424'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In addition, drug-induced <b>hemolytic anemia</b> may occur with the use of NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23710383','lexi-content-ref-33654588','lexi-content-ref-25247621','lexi-content-ref-8443483','lexi-content-ref-3545733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23710383','lexi-content-ref-33654588','lexi-content-ref-25247621','lexi-content-ref-8443483','lexi-content-ref-3545733'])">Ref</a></span>). Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, <b>agranulocytosis</b>, <b>aplastic anemia</b>, neutropenia, <b>thrombocytopenia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33100559','lexi-content-ref-8379803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33100559','lexi-content-ref-8379803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Prolonged bleeding time: Inhibition of cyclooxygenase (COX)-1 by nonselective NSAIDs causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A<sub>2</sub> (TxA<sub>2</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2082316','lexi-content-ref-32760620','lexi-content-ref-2724096','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2082316','lexi-content-ref-32760620','lexi-content-ref-2724096','lexi-content-ref-1321554'])">Ref</a></span>). As a result, patients may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29891025','lexi-content-ref-2082316','lexi-content-ref-32760620','lexi-content-ref-18193919','lexi-content-ref-9422305','lexi-content-ref-19269020','lexi-content-ref-1321554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29891025','lexi-content-ref-2082316','lexi-content-ref-32760620','lexi-content-ref-18193919','lexi-content-ref-9422305','lexi-content-ref-19269020','lexi-content-ref-1321554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Blood dyscrasias: Not clearly established; anemia may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. May also be attributed to a drug-dependent immune mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3547002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3547002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration of an NSAID (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-32760620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037526','lexi-content-ref-18359332','lexi-content-ref-32760620'])">Ref</a></span>). Bleeding time was prolonged within hours of administration of a single dose of ketorolac in healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14523887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14523887'])">Ref</a></span>); postoperatively, bleeding has been reported after a single dose of ketorolac (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32760620','lexi-content-ref-8797556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32760620','lexi-content-ref-8797556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bleeding events:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting coagulation disorders</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15668365','lexi-content-ref-24733305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15668365','lexi-content-ref-24733305'])">Ref</a></span>), antithrombotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25710657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25710657'])">Ref</a></span>), antiplatelet agents [eg, aspirin, P2Y12 inhibitors], selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>), or serotonin norepinephrine reuptake inhibitors)</p>
<p style="text-indent:-2em;margin-left:8em;">- Use during and immediately following surgical procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22434401','lexi-content-ref-24338331','lexi-content-ref-8797556','lexi-content-ref-23175926','lexi-content-ref-8569017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22434401','lexi-content-ref-24338331','lexi-content-ref-8797556','lexi-content-ref-23175926','lexi-content-ref-8569017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>• Note: </b>Some studies have suggested that ketorolac is not associated with increased bleeding in the perioperative period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24572864','lexi-content-ref-32393370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24572864','lexi-content-ref-32393370'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Age &lt;21 days and &lt;37 weeks corrected gestational age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aldrink.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aldrink.2011'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal anti-inflammatory drugs (NSAIDs), including ketorolac, may cause mild transaminase elevations, especially with higher doses; one study found no association between use of parenteral ketorolac and hepatoxic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9385304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9385304'])">Ref</a></span>). Rarely, serious liver injury may occur following use of NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794','lexi-content-ref-30112779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794','lexi-content-ref-30112779'])">Ref</a></span>). Cholestatic and mixed patterns of injury have been reported with the use of NSAIDs. NSAID-induced hepatic effects may occur following severe hypersensitivity reactions (eg, toxic epidermal necrosis, Stevens-Johnson syndrome) and are characterized by immune-mediated symptoms (eg, fever rash, eosinophilia, lymphadenopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8759674','lexi-content-ref-276660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8759674','lexi-content-ref-276660'])">Ref</a></span>). Severe liver injury requiring liver transplantation has also been reported following use of NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23325533','lexi-content-ref-12358284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23325533','lexi-content-ref-12358284'])">Ref</a></span>). Most cases of liver injury are likely reversible following discontinuation; full recovery may take several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-276660','lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-276660','lexi-content-ref-31984540'])">Ref</a></span>). However, chronic vanishing bile duct syndrome with chronic liver failure has been reported following cholestatic liver injury secondary to ibuprofen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8759674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8759674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; dose-related has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794'])">Ref</a></span>). Proposed mechanisms include a toxic metabolite or a hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31984540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of NSAID-induced hepatotoxicity is generally classified as moderate (30 to 90 days) to long (&gt;90 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24935270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24935270'])">Ref</a></span>). For ibuprofen, a mean time of 12 days (range: 1 to 42 days) was reported in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31984540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31984540'])">Ref</a></span>). Treatment with ketorolac is limited to short-term use (ie, 5 days).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991794'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior NSAID-related liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: Cross-reactivity may occur between groups of NSAIDs (eg, cross-reactivity between propionic acid derivatives [ibuprofen, naproxen, ketoprofen]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3115366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3115366'])">Ref</a></span>). Ketorolac is a member of the pyrrolo-pyrrole group of NSAIDs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions</b> (immediate and delayed) involving the skin (eg, <b>angioedema</b>, <b>urticaria</b>), airways (eg, dyspnea, rhinorrhea), and/or other organs have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Clinical phenotypes of nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions include NSAID-exacerbated respiratory disease (NERD), NSAID-induced urticaria/angioedema (NIUA), NSAID-exacerbated cutaneous disease (NECD), and single NSAID-induced urticaria/angioedema or anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29255644','lexi-content-ref-1421646','lexi-content-ref-24117484','lexi-content-ref-36757490','lexi-content-ref-8189303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29255644','lexi-content-ref-1421646','lexi-content-ref-24117484','lexi-content-ref-36757490','lexi-content-ref-8189303'])">Ref</a></span>). Delayed hypersensitivity reactions, including <b>drug rash with eosinophilia and systemic symptoms</b> (DRESS), and<b> Stevens-Johnson syndrome </b>(SJS)/<b>toxic epidermal necrolysis</b> (TEN) have also been associated with ketorolac.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate reactions</b>: Non–dose-related; most reactions (ie, NERD, NECD, NIUA) are nonimmunologic related to inhibition of cyclooxygenase (COX)-1 with subsequent activation of mast cells and eosinophils causing release of inflammatory mediators including cysteinyl-leukotrienes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). Some immediate reactions may be IgE mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11240963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11240963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Delayed reactions:</b> Delayed hypersensitivity reactions are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate reactions: </b>Rapid; generally occurs within 1 hour of administration but may occur several hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Delayed reactions (including DRESS and SJS/TEN):</b> Varied; generally occurs after 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of chronic rhinosinusitis with nasal polyps, family history of NERD, and/or severe asthma may increase the risk of NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29255644','lexi-content-ref-8115903','lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29255644','lexi-content-ref-8115903','lexi-content-ref-30216468'])">Ref</a></span>). The prevalence of NERD in adult patients with asthma is ~10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30216468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30216468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic urticaria increases the risk of NECD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24117484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24117484'])">Ref</a></span>). NSAID-induced reactions are less frequent and less intense when chronic urticaria is in remission or under control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749768'])">Ref</a></span>). Approximately 12% to 30% of patients with chronic idiopathic urticaria develop exacerbations of their disease with use of ketorolac and other COX-1 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28483309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28483309'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between aspirin and NSAIDs, including ketorolac (with predominant COX-1 inhibition) have been described in patients with a history of NERD, NECD, and NIUA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8934961','lexi-content-ref-8115903','lexi-content-ref-24117484','lexi-content-ref-10877042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8934961','lexi-content-ref-8115903','lexi-content-ref-24117484','lexi-content-ref-10877042'])">Ref</a></span>). Cross-reactivity between aspirin/NSAID and acetaminophen, a weak COX inhibitor, and between aspirin/NSAID and nonselective COX-2 inhibitors (eg, meloxicam, nimesulide) may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-17609236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-17609236'])">Ref</a></span>). Although selective COX-2 inhibitors (eg, celecoxib, etoricoxib) are generally tolerated in patients with NERD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21631520','lexi-content-ref-30207919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21631520','lexi-content-ref-30207919'])">Ref</a></span>), cross-reactions may occur, especially in patients with histories of urticaria/angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21834936','lexi-content-ref-24587953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21834936','lexi-content-ref-24587953'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Kidney effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hemodynamically mediated<b> acute kidney injury</b> (AKI) may occur following use of either cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs) (ie, coxibs) or nonselective NSAIDs, including ketorolac (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-8477132','lexi-content-ref-34553259','lexi-content-ref-7942813','lexi-content-ref-37004573','lexi-content-ref-29075132','lexi-content-ref-23360563','lexi-content-ref-25439535','lexi-content-ref-17005625','lexi-content-ref-26377377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-8477132','lexi-content-ref-34553259','lexi-content-ref-7942813','lexi-content-ref-37004573','lexi-content-ref-29075132','lexi-content-ref-23360563','lexi-content-ref-25439535','lexi-content-ref-17005625','lexi-content-ref-26377377'])">Ref</a></span>); the risk may be greater with nonselective NSAIDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26945352','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26945352','lexi-content-ref-10390124'])">Ref</a></span>). The risk of developing AKI is decreased upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8219436','lexi-content-ref-7942813','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8219436','lexi-content-ref-7942813','lexi-content-ref-10390124'])">Ref</a></span>); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; inhibition of COX-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3045551','lexi-content-ref-10390124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3045551','lexi-content-ref-10390124'])">Ref</a></span>). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25439535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25439535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; may occur within hour to days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8219436','lexi-content-ref-34553259','lexi-content-ref-8007038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8219436','lexi-content-ref-34553259','lexi-content-ref-8007038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• AKI:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:8em;">- Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:8em;">- ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chan.2014','lexi-content-ref-26377377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chan.2014','lexi-content-ref-26377377'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• <b>Note: </b>NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23453549','lexi-content-ref-23360563']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23453549','lexi-content-ref-23360563'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemodynamically mediated AKI:</p>
<p style="text-indent:-2em;margin-left:8em;">- Preexisting conditions that result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32479922','lexi-content-ref-34553259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32479922','lexi-content-ref-34553259'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">• Volume depletion (eg, due to concomitant diuretic use, vomiting)</p>
<p style="text-indent:-2em;margin-left:10em;">• Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15754275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15754275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Cirrhosis and ascites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-447795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-447795'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:8em;">- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chan.2014','lexi-content-ref-29799625','lexi-content-ref-34553259','lexi-content-ref-23299844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chan.2014','lexi-content-ref-29799625','lexi-content-ref-34553259','lexi-content-ref-23299844'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8346957"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for ketorolac.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, dyspepsia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, diarrhea, flatulence, gastrointestinal fullness, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, heartburn, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, prolonged bleeding time, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (IM, IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal function abnormality</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, palpitations, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, ecchymoses, pallor, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst, weight changes</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dysgeusia, eructation, esophagitis, gastritis, glossitis, hematemesis, increased appetite, melena, rectal hemorrhage, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dysuria, exacerbation of urinary frequency, hematuria, infertility, oliguria, proteinuria, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, abnormality in thinking, anxiety, asthenia, confusion, depression, euphoria, extrapyramidal reaction, hallucination, insomnia, lack of concentration, malaise, nervousness, paresthesia, stupor, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis, polyuria, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, cough, dyspnea, epistaxis, pulmonary edema, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Coronary thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Peptic ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, bradycardia, cardiac arrhythmia, chest pain, flushing, hypotension, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia (Haragsim 1994), hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Famularo 2002), aphthous stomatitis, exacerbation of Crohn disease, exacerbation of ulcerative colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, hemolytic-uremic syndrome (Randi 1993), lymphadenopathy, pancytopenia, postoperative hematoma, postoperative wound bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatotoxicity (idiosyncratic) (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Yousefi 2020), angioedema (Shapiro 1994), drug reaction with eosinophilia and systemic symptoms, hypersensitivity reaction, nonimmune anaphylaxis (Goetz 1992), tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis, coma, psychosis, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Haragsim 1994), flank pain, nephrotic syndrome, renal papillary necrosis (Witting 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, laryngeal edema, pneumonia, respiratory depression</p></div>
<div class="block coi drugH1Div" id="F8345801"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ketorolac, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or any component of the formulation; active or history of peptic ulcer disease; recent or history of GI bleeding or perforation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; advanced renal disease or patients at risk for renal failure due to volume depletion; prophylactic analgesic before any major surgery; suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding; concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline; epidural or intrathecal administration (injection only); use in the setting of coronary artery bypass graft surgery; labor and delivery.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Intraoperative use; coagulation disorders; active GI bleeding; postoperative patients with high-bleeding risk; severe uncontrolled heart failure; inflammatory bowel disease; severe hepatic impairment or active hepatic disease; moderate to severe renal impairment (serum creatinine &gt;442 micromol/L and/or creatinine clearance &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; third trimester of pregnancy; breast-feeding; use in children and adolescents &lt;18 years of age</p></div>
<div class="block war drugH1Div" id="F8345802"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in patients ≥65 years of age, in patients with diabetes or renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic disease; patients with advanced hepatic disease are at an increased risk of GI bleeding and kidney failure with NSAIDs (AASLD [Biggins 2021]; AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age are at greater risk for serious GI, cardiovascular, and/or renal adverse events; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878744"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In neonates, bleeding events have been reported; in a retrospective analysis of 57 postsurgical neonates and infants (age range: 0 to 3 months), 17.2% of patients experienced a bleeding event, most were PNA &lt;21 days and those with PNA &lt;14 days had a significantly higher risk than older neonates (Aldrink 2011). Acute kidney injury (AKI) has been observed in pediatric patients; with ketorolac use following cardiothoracic surgery, an increased risk of AKI was observed in neonates and infants who underwent a bidirectional Glenn procedure and were receiving concomitant aspirin therapy (Moffett 2013).</p></div>
<div class="block foc drugH1Div" id="F8353206"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ReadySharp Ketorolac: 15 mg/mL [DSC] [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as tromethamine [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as tromethamine [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F8345793"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8353221"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ketorolac Tromethamine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/mL (per mL): $0.95 - $4.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/mL (per mL): $1.04 - $7.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ketorolac Tromethamine Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg/2 mL (per mL): $0.54 - $4.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ketorolac Tromethamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.16 - $2.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869215"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toradol: 10 mg/mL (1 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toradol: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block admp drugH1Div" id="F52614365"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food or milk to decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer slowly and deeply into muscle; 60 mg per 2 mL vial is for IM use only.</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Administer undiluted over at least 15 seconds; in children, ketorolac has been infused over 1 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7803871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7803871'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F8352025"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May administer with food to reduce GI upset.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer slowly and deeply into the muscle.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer IV bolus over a minimum of 15 seconds.</p></div>
<div class="block sts drugH1Div" id="F8349367"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Injection is clear and has a slight yellow color. Precipitation may occur at relatively low pH values.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F). Protect from light and excessive humidity.</p></div>
<div class="block meg drugH1Div" id="F8345784"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg%3D%3D&amp;TOPIC_ID=16007" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570611"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">IM, IV: Short-term (≤5 days) management of moderately severe acute pain requiring analgesia at the opioid level, usually in the postoperative setting (FDA approved in ages ≥17 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Short-term (≤5 days) management of moderately severe acute pain, usually postoperative pain, and only as continuation therapy of IM or IV ketorolac (FDA approved in ages ≥17 years and adults).</p></div>
<div class="block mst drugH1Div" id="F8320263"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ketorolac may be confused with Ketalar, ketamine, methadone</p>
<p style="text-indent:-2em;margin-left:4em;">Toradol may be confused with Foradil, Inderal, Tegretol, traMADol, tromethamine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Ketorolac is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to an increased risk of GI bleeding, peptic ulcer disease, and acute kidney injury (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Toradol [Canada and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299558"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F8347281"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Ketorolac (Systemic) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.  Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Ketorolac (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: Ketorolac (Systemic) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Ketorolac (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).  Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F8349365"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">High-fat meals may delay time to peak (by ~1 hour) and decrease peak concentrations. Management: Administer tablet with food or milk to decrease gastrointestinal distress.</p></div>
<div class="block dic drugH1Div" id="F8350489"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer tablet with food or milk to decrease gastrointestinal distress.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307973"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Nonsteroidal anti-inflammatory drugs may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.</p></div>
<div class="block pri drugH1Div" id="F8345797"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ketorolac crosses the placenta (Walker 1988).</p>
<p style="text-indent:0em;margin-top:2em;">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage, have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, prescribing information for ketorolac specifically states use should be avoided starting at 30 weeks' gestation</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of ketorolac may be altered. Ketorolac has S and R enantiomers; pharmacologic activity is associated with S-ketorolac enantiomer. The clearance of S-ketorolac was found to increase at delivery compared to postpartum values; the peak serum concentration was decreased (Kulo 2017; Välitalo 2017).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: The use of ketorolac in labor and delivery is contraindicated because it may adversely affect fetal circulation and inhibit uterine contractions. The risk of uterine hemorrhage may be increased. </b>NSAIDs may be used as part of multimodal pain management following cesarean delivery (ACOG 2019).</p></div>
<div class="block mopp drugH1Div" id="F53570612"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of pain relief (eg, increased appetite and activity); BUN, SCr, urine output, LFTs, CBC and platelets, serum electrolytes, occult blood loss, blood pressure; fluid retention/edema and weight gain; signs and symptoms of GI bleeding.</p></div>
<div class="block rerp drugH1Div" id="F53570060"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Serum concentration:</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic: 0.3 to 5 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Toxic: &gt;5 mcg/mL.</p></div>
<div class="block pha drugH1Div" id="F8349370"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>
<p style="text-indent:0em;margin-top:2em;">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.</p></div>
<div class="block phk drugH1Div" id="F8349373"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Analgesic: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Analgesic: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Analgesic: 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed (100%), administration after a high-fat meal decreased peak and delayed time to peak concentrations by ~1 hour; IM: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Poor penetration into cerebrospinal fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: V<sub>dss</sub>: ~0.2 L/kg (McLay 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;16 years: V<sub>dss</sub>: 0.18 L/kg (McLay 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: V<sub>d</sub> beta: Oral, IM: 0.17 ± 0.04 L/kg; IV: 0.21 ± 0.04 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; undergoes hydroxylation and glucuronide conjugation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral, IM: 100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months: S-enantiomer: 0.83 ± 0.7 hours; R-enantiomer: 4 ± 0.8 hours (Lynn 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents ≤16 years: 3 ± 1.1 hours (Dsida 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Mean: ~5 hours; Range: 2 to 9 hours [S-enantiomer ~2.5 hours (biologically active); R-enantiomer ~5 hours]; Prolonged 30% to 50% in elderly.</p>
<p style="text-indent:-2em;margin-left:6em;">With renal impairment: S<sub>cr</sub> 1.9 to 5 mg/dL: Mean: ~11 hours; Range: 4 to 19 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Renal dialysis patients: Mean: ~14 hours; Range: 8 to 40 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~45 minutes; IM: ~30 to 45 minutes; IV: 1 to 3 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (92%, ~60% as unchanged drug); feces ~6%.</p></div>
<div class="block phksp drugH1Div" id="F51197823"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced and half-life is increased in renal impairment. AUC is increased by ~100% and volume of distribution increases.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: V<sub>d</sub> and clearance are higher in pediatric patients compared to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Half-life is longer in patients ≥65 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961984"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Blocadol | Dipgix | Dolac | Dolten | Duprac | Kelac | Keramix | Ketial | Ketodol | Ketomar | Ketorolac | Ketorolac Ahimsa | Ketorolac Fabra | Ketorolac hlb | Ketorolac labsa | Ketorolac Northia | Ketorolac Richet | Ketorolac vannier | Ketorolac vent 3 | Kpan | Sinalgico | Teledol | Tenkdol | Unicalm | Zerodol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-ketorolac | Ketoral | Ketorolac act | Ketorolac baxter | Ketorolac juno | Ketorolac kabi | Toradol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Actifast | Analac | Angesic | Deltora | Doloket | Doltro | Emodol | Etorac | Eurolac | Kelorac | Kepros | Ket | Keteks | Ketoact | Ketoflex | Ketolab | Ketolac | Ketonaaf | Ketoprix | Ketorin | Ketorolac | Ketoshot | Kilpan | Knil | Lacor | Lopadol | Lupelac | Maxdol | Ofpain | Oradol | Orc | Pair | Perilac | Repopain | Romilac | Rotalac | Rotek | Sanoket | SB ketor | Surpim | Temoket | Todol | Tolec | Toradol | Toralin | Toramax | Toro | Toroaid | Torosic | Winop | Xenolac | Xidolac | Zepac | Zeropain</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tora-dol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Toroxim</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Algipres | Brodifac | Burten | Dilox | Dolgenal | Ketorolaco trometamol | Netaf | Syndol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ke duo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Anaxer | Bilkinase | Keradol | Ketorolaco | Ketorolaco trometamina | Ketron | Kine</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Analxican | Angess | Dolgenal | Dolten | Fraterolac | Iberolaco | Keradol | Ketomax | Ketorolac | Ketorolaco | Ketramol | Ketron | Supradol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Altrom | Brodifac | Burten | Dolgenal | Fadol | Kelko | Ketorolaco | Notolac | Proalgan | Rolesen | Toradol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adolor | Fam | Ketolac | Ketoral | Ketrac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Algikey | Droal | Ketorolaco trometamol Domac | Ketorolaco trometamol Lesvi | Tonum | Toradol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Dolket</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ketorolac trometamol normon | Toradol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Farpain | Ketorolac | Latorec | Teranol | Toradol | Toramine | Trolac | Xevolac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Topadol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cadolac | Dolac | Fortral kt | Kelac | Kenalfin | Ketanov | Keter | Ketogon dt | Ketorol | Ketorol DT | Ketro | Nato | Nodine | Painlok dt | T lac | Torolac | Zorovon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lixidol | Tora Dol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dolac | Rolac</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kentorac | Kerola | Kerolmin | Ketolacin | Ketoracin | Ketro | Tarasyn | Tolac | Trolac</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ketolac</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dolak | Ketanov | Ketorol | Nato</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dolak | Ketanov | Ketorol | Ketorolak</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ainelac | Alypharm | Apotoke | Brunacol | Celfax | Dobelor | Doket | Dolac | Dolikan | Dolotor | Efimerol | Estopein | Finlac | Gesilac | Glicima | Italker | K2sol | Katamisine | Kendol | Kendolit t | Ketanor | Ketorolaco | Ketorolaco gi kend | Ketorolaco gi kene | Ketorolaco gi serr | Ketoxil | Ketrol | Koxalgen | Lacdol | Lacdol s | Lacomin | Landaco | Lorotec | Mavidol | Mevidir | Novakerol | Onemer | Oro k | Relkedol | Rolesen | Rometran k | Supradol | Toloran | Toral | Torkol | Trodorol | Ultilap | Verolak | Vitoket | Voydol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ketanov | Keto | Toradol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dolac | Reals ketorolac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Algias | Analgesium | Anku | Apten | Celgese | Cortalen | Dolmax | Dolnix | Dolofac | Doloketal | Dolorex | Doltrex | Grabia | Halgeze | Hanalgeze | Kedol | Keradol | Ketaxal | Ketodol | Ketomax | Ketomed | Ketomolargesico | Ketorolaco | Ketorolaco fmndtria | Ketorolaco MF | Ketorolaco trometamina | Ketorolin | Ketossone | Ketovet | Ketozol | Ketradol | Kine | Kitamass | Maxidol | Maxis | Q-dolese | Quetorol | Rolesen | Sanagese | Toralac</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alore | Eurolac | Ketanov | Ketero | Keto | Ketomed</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">K lac | Kerol | Ketin | Orkit | Toradol | Toraject | Torapan | Xevolac | Yukon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ketorolac | Ketorolac tromethaline | Toradol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Anador | Dilamol | Dilox | Dolgenal | Dolo galen | Dolomedin | Doloren | Dolostop | Dolsed | Dolten | Doxyclin | Hontocal | Kedolac | Keto odontol | Ketorolac dallas | Ketorolac empa | Ketorolac medinac | Ketorolac millet | Ketorolac pasteur | Prodent forte | Quetorol | Rapidol | Sauran forte | Tetralgin | Toralgin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fam | Tora-Dol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ketanov | Ketorol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adolor | Dolac | Dolak | Ketalgin | Ketanov | Ketofreel | Ketokam | Ketolac | Ketorol | Ketorolac | Ketorolac Obl | Ketrodol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Toradol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ketolac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ketrodol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Analif | Inco | Kelorac | Kidoton | Kop | Painoff | Sukerin | Suketon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ambit | Blockpain | Emodol | Ketalgin | Ketalgin long | Ketanov | Ketolex | Ketolong | Ketorol | Ketorolac | Ketorolac jayson | Ketorolac norton | Ketorolac zdorovje</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dolgenal | Dolten | Eleadol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biolak | Dolak | Kelac | Ketolac | Ketorolac | Ketorolac trometamina | Ketorolaco | Kettal | Notolac</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tora-dol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Dolac</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation.</i> 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8759674">
<a name="8759674"></a>Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. <i>Am J Gastroenterol</i>. 1996;91(8):1626-1630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8759674/pubmed" id="8759674" target="_blank">8759674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aldrink.2011">
<a name="Aldrink.2011"></a>Aldrink JH, Ma M, Wang W, Caniano DA, Wispe J, Puthoff T. Safety of ketorolac in surgical neonates and infants 0 to 3 months old. <i>J Pediatr Surg</i>. 2011;46(6):1081-1085</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891025">
<a name="29891025"></a>Alqahtani Z, Jamali F. Clinical Outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: A systematic review. <i>J Pharm Pharm Sci</i>. 2018;21(1s):29854. doi:10.18433/jpps29854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29891025/pubmed" id="29891025" target="_blank">29891025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079598">
<a name="17079598"></a>American Academy of Pediatrics Committee on Fetus and Newborn; American Academy of Pediatrics Section on Surgery; Canadian Paediatric Society Fetus and Newborn Committee, et al, "Prevention and Management of Pain in the Neonate: An Update," <i>Pediatrics</i>, 2006, 118(5):2231-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/17079598/pubmed" id="17079598" target="_blank">17079598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACS.1">
<a name="ACS.1"></a>American College of Surgeons (ACS). ACS Trauma Quality Programs best practices guidelines for acute pain management in trauma patients. https://www.facs.org/-/media/files/quality-programs/trauma/tqip/acute_pain_guidelines.ashx. Published November 2020. Accessed August 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017. Erratum in: <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714. Dosage error in article text.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3115366">
<a name="3115366"></a>Andrejak M, Davion T, Gineston JL, Capron JP. Cross hepatotoxicity between non-steroidal anti-inflammatory drugs. <i>Br Med J (Clin Res Ed)</i>. 1987;295(6591):180-181. doi:10.1136/bmj.295.6591.180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3115366/pubmed" id="3115366" target="_blank">3115366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32479922">
<a name="32479922"></a>Baker M, Perazella MA. NSAIDs in CKD: are they safe? <i>Am J Kidney Dis</i>. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32479922/pubmed" id="32479922" target="_blank">32479922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28487435">
<a name="28487435"></a>Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. <i>BMJ</i>. 2017;357:j1909. doi:10.1136/bmj.j1909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28487435/pubmed" id="28487435" target="_blank">28487435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23710383">
<a name="23710383"></a>Barbaryan A, Iyinagoro C, Nwankwo N, et al. Ibuprofen-induced hemolytic anemia. <i>Case Rep Hematol</i>. 2013;2013:142865. doi:10.1155/2013/142865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23710383/pubmed" id="23710383" target="_blank">23710383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668365">
<a name="15668365"></a>Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. <i>Arch Intern Med</i>. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15668365/pubmed" id="15668365" target="_blank">15668365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24663106">
<a name="24663106"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24663106/pubmed" id="24663106" target="_blank">24663106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23726390">
<a name="23726390"></a>Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23726390/pubmed" id="23726390" target="_blank">23726390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682313">
<a name="24682313"></a>Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. <i>World J Surg</i>. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24682313/pubmed" id="24682313" target="_blank">24682313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18836135">
<a name="18836135"></a>Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i>. 2008;118(18):1894-1909. doi:10.1161/CIRCULATIONAHA.108.191087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/18836135/pubmed" id="18836135" target="_blank">18836135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23558845">
<a name="23558845"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23558845/pubmed" id="23558845" target="_blank">23558845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23453549">
<a name="23453549"></a>Brophy PD. Changing the paradigm in pediatric acute kidney injury. <i>J Pediatr</i>. 2013;162(6):1094-1096. doi:10.1016/j.jpeds.2013.01.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23453549/pubmed" id="23453549" target="_blank">23453549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7803871">
<a name="7803871"></a>Buck ML. Clinical Experience With Ketorolac in Children. <i>Ann Pharmacother</i>. 1994;28(9):1009-1013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/7803871/pubmed" id="7803871" target="_blank">7803871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2178916">
<a name="2178916"></a>Buckley MM and Brogden RN, "Ketorolac. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential," <i>Drugs</i>, 1990, 39(1):86-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/2178916/pubmed" id="2178916" target="_blank">2178916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902701">
<a name="11902701"></a>Burd RS and Tobias JD, "Ketorolac for Pain Management After Abdominal Surgical Procedures in Infants," <i>South Med J</i>, 2002, 95(3):331-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11902701/pubmed" id="11902701" target="_blank">11902701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15837265">
<a name="15837265"></a>Capone ML, Sciulli MG, Tacconelli S, et al, “Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,” <i>J Am Coll Cardiol</i>, 2005, 45(8):1295-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15837265/pubmed" id="15837265" target="_blank">15837265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15037526">
<a name="15037526"></a>Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i>. 2004;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15037526/pubmed" id="15037526" target="_blank">15037526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carpuject.1">
<a name="Carpuject.1"></a>Carpuject (ketorolac tromethamine) [prescribing information]. Lake Forest, IL: Hospira, Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137151">
<a name="23137151"></a>Castellsague J, Riera-Guardia N, Calingaert B, et al; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). <i>Drug Saf</i>. 2012;35(12):1127-1146. doi:10.2165/11633470-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23137151/pubmed" id="23137151" target="_blank">23137151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11509629">
<a name="11509629"></a>Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. <i>J Immunol</i>. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11509629/pubmed" id="11509629" target="_blank">11509629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22434401">
<a name="22434401"></a>Cawthorn TR, Phelan R, Davidson JS, Turner KE. Retrospective analysis of perioperative ketorolac and postoperative bleeding in reduction mammoplasty. <i>Can J Anaesth</i>. 2012;59(5):466-472. doi:10.1007/s12630-012-9682-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/22434401/pubmed" id="22434401" target="_blank">22434401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16534006">
<a name="16534006"></a>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. <i>Circulation</i>. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/16534006/pubmed" id="16534006" target="_blank">16534006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24338331">
<a name="24338331"></a>Chan DK, Parikh SR. Perioperative ketorolac increases post-tonsillectomy hemorrhage in adults but not children. <i>Laryngoscope</i>. 2014;124(8):1789-1793. doi:10.1002/lary.24555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24338331/pubmed" id="24338331" target="_blank">24338331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chan.2014">
<a name="Chan.2014"></a>Chan J, Bajnath A, Fromkin B, et al. Ketorolac prescribing practices in an acute care hospital and the incidence of acute renal failure. <i>World Journal of Nephrology &amp; Urology</i>. 2014;3(3):113-117.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8934961">
<a name="8934961"></a>Chen AH, Bennett CR. Ketorolac-induced bronchospasm in an aspirin-intolerant patient. <i>Anesth Prog</i>. 1994;41(4):102-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8934961/pubmed" id="8934961" target="_blank">8934961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964481">
<a name="11964481"></a>Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. <i>Science</i>. 2002;296(5567):539-541. doi:10.1126/science.1068711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11964481/pubmed" id="11964481" target="_blank">11964481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945352">
<a name="26945352"></a>Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: A nested case-control cohort study. <i>Medicine (Baltimore)</i>. 2016;95(9):e2645. doi:10.1097/MD.0000000000002645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26945352/pubmed" id="26945352" target="_blank">26945352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council [published correction appears in <i>J Pain</i>. 2016;17(4):508-510]. <i>J Pain</i>. 2016;17(2):131-157. doi: 10.1016/j.jpain.2015.12.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3259170">
<a name="3259170"></a>Conrad KA, Fagan TC, Mackie MJ, Mayshar PV. Effects of ketorolac tromethamine on hemostasis in volunteers. <i>Clin Pharmacol Ther</i>. 1988;43(5):542-546. doi:10.1038/clpt.1988.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3259170/pubmed" id="3259170" target="_blank">3259170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8219436">
<a name="8219436"></a>Corelli RL, Gericke KR. Renal insufficiency associated with intramuscular administration of ketorolac tromethamine. <i>Ann Pharmacother</i>. 1993;27(9):1055-1057. doi:10.1177/106002809302700908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8219436/pubmed" id="8219436" target="_blank">8219436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626023">
<a name="9626023"></a>Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.<i> Am J Med</i>. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9626023/pubmed" id="9626023" target="_blank">9626023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31273431">
<a name="31273431"></a>Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/31273431/pubmed" id="31273431" target="_blank">31273431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733305">
<a name="24733305"></a>Davidson BL, Verheijen S, Lensing AW, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. <i>JAMA Intern Med</i>. 2014;174(6):947-953. doi:10.1001/jamainternmed.2014.946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24733305/pubmed" id="24733305" target="_blank">24733305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19134246">
<a name="19134246"></a>Dawkins TN, Barclay CA, Gardiner RL, et al, "Safety of Intravenous Use of Ketorolac in Infants Following Cardiothoracic Surgery," <i>Cardiol Young</i>, 2009, 19(1):105-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/19134246/pubmed" id="19134246" target="_blank">19134246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799625">
<a name="29799625"></a>Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: Implications of changes in renal function associated with concurrent use. <i>J Clin Pharmacol</i>. 2018;58(11):1443-1451. doi:10.1002/jcph.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29799625/pubmed" id="29799625" target="_blank">29799625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21834936">
<a name="21834936"></a>Doña I, Blanca-López N, Jagemann LR, et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2011;66(11):1428-1433. doi:10.1111/j.1398-9995.2011.02684.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/21834936/pubmed" id="21834936" target="_blank">21834936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991794">
<a name="26991794"></a>Donati M, Conforti A, Lenti MC, et al; DILI-IT Study Group. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. <i>Br J Clin Pharmacol</i>. 2016;82(1):238-248. doi:10.1111/bcp.12938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26991794/pubmed" id="26991794" target="_blank">26991794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11812682">
<a name="11812682"></a>Dsida RM, Wheeler M, Birmingham PK, et al, "Age-Stratified Pharmacokinetics of Ketorolac Tromethamine in Pediatric Surgical Patients," <i>Anesth Analg</i>, 2002, 94(2):266-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11812682/pubmed" id="11812682" target="_blank">11812682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18068059">
<a name="18068059"></a>Engoren MC, Habib RH, Zacharias A, et al. Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: a propensity-matched study. <i>J Cardiothorac Vasc Anesth</i>. 2007;21(6):820-826. doi:10.1053/j.jvca.2007.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/18068059/pubmed" id="18068059" target="_blank">18068059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33654588">
<a name="33654588"></a>Esteves A, Teixeira da Silva F, Carvalho J, Carvoeiro A, Felgueiras P. Diclofenac-induced immune hemolytic anemia: A case report and review of literature. <i>Cureus</i>. 2021;13(1):e12903. doi:10.7759/cureus.12903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/33654588/pubmed" id="33654588" target="_blank">33654588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7486100">
<a name="7486100"></a>Etches RC, Warriner CB, Badner N, et al. Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty. <i>Anesth Analg</i>. 1995;81(6):1175-1180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/7486100/pubmed" id="7486100" target="_blank">7486100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11873116">
<a name="11873116"></a>Famularo G, Bizzarri C, Nicotra GC. Acute pancreatitis caused by ketorolac tromethamine. <i>J Clin Gastroenterol</i>. 2002;34(3):283-284. doi:10.1097/00004836-200203000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11873116/pubmed" id="11873116" target="_blank">11873116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Announcement. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDS) can cause heart attacks or strokes. July 9, 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29255644">
<a name="29255644"></a>Fernandes V, Alfaro TM, Baptista JP, Regateiro FS, Fradinho F, Cordeiro CR. Severe ketorolac-induced asthma diagnosed by chest computed tomography. <i>J Thorac Dis</i>. 2017;9(Suppl 16):S1567-S1569. doi:10.21037/jtd.2017.11.36<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29255644/pubmed" id="29255644" target="_blank">29255644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8477132">
<a name="8477132"></a>Fong J, Gora ML. Reversible renal insufficiency following ketorolac therapy. <i>Ann Pharmacother</i>. 1993;27(4):510-512. doi:10.1177/106002809302700422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8477132/pubmed" id="8477132" target="_blank">8477132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9187531">
<a name="9187531"></a>Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. <i>Drug Saf</i>. 1997;16(5):309-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9187531/pubmed" id="9187531" target="_blank">9187531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24523483">
<a name="24523483"></a>Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. <i>Neurology</i>. 2014;82(11):976-983. doi:10.1212/WNL.0000000000000223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24523483/pubmed" id="24523483" target="_blank">24523483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32072099">
<a name="32072099"></a>Friedrichsdorf SJ, Goubert L. Pediatric pain treatment and prevention for hospitalized children. <i>Pain Rep</i>. 2019;5(1):e804. doi:10.1097/PR9.0000000000000804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32072099/pubmed" id="32072099" target="_blank">32072099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8364288">
<a name="8364288"></a>Fuller DK, Kalekas PJ. Ketorolac and gastrointestinal ulceration. <i>Ann Pharmacother</i>. 1993;27(7-8):978-979. doi:10.1177/106002809302700731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8364288/pubmed" id="8364288" target="_blank">8364288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9437376">
<a name="9437376"></a>García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. <i>Arch Intern Med</i>. 1998;158(1):33-39. doi:10.1001/archinte.158.1.33<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9437376/pubmed" id="9437376" target="_blank">9437376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25247621">
<a name="25247621"></a>Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. <i>Immunohematology</i>. 2014;30(2):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25247621/pubmed" id="25247621" target="_blank">25247621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18359332">
<a name="18359332"></a>Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. <i>Am J Cardiol</i>. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/18359332/pubmed" id="18359332" target="_blank">18359332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24572864">
<a name="24572864"></a>Gobble RM, Hoang HLT, Kachniarz B, Orgill DP. Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. <i>Plast Reconstr Surg</i>. 2014;133(3):741-755. doi:10.1097/01.prs.0000438459.60474.b5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24572864/pubmed" id="24572864" target="_blank">24572864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1421646">
<a name="1421646"></a>Goetz CM, Sterchele JA, Harchelroad FP. Anaphylactoid reaction following ketorolac tromethamine administration. <i>Ann Pharmacother</i>. 1992;26(10):1237-1238. doi:10.1177/106002809202601008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/1421646/pubmed" id="1421646" target="_blank">1421646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.2013">
<a name="Golightly.2013"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>. New York, NY: Springer Science; 2013</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2082316">
<a name="2082316"></a>Greer IA. Effects of ketorolac tromethamine on hemostasis. <i>Pharmacotherapy</i>. 1990;10(6 ( Pt 2)):71S-76S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/2082316/pubmed" id="2082316" target="_blank">2082316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23325533">
<a name="23325533"></a>Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. <i>Drug Saf</i>. 2013;36(2):135-144. doi:10.1007/s40264-012-0013-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23325533/pubmed" id="23325533" target="_blank">23325533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30112779">
<a name="30112779"></a>Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(11):1174-1181. doi:10.1002/pds.4640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30112779/pubmed" id="30112779" target="_blank">30112779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365927">
<a name="15365927"></a>Gupta A, Daggett C, Drant S, et al, "Prospective Randomized Trial of Ketorolac After Congenital Heart Surgery," <i>J Cardiothorac Vasc Anesth</i>, 2004, 18(4):454-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15365927/pubmed" id="15365927" target="_blank">15365927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675931">
<a name="15675931"></a>Gupta A, Daggett C, Ludwick J, et al, "Ketorolac After Congenital Heart Surgery: Does It Increase the Risk of Significant Bleeding Complications?" <i>Paediatr Anaesth</i>, 2005, 15(2):139-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15675931/pubmed" id="15675931" target="_blank">15675931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32760620">
<a name="32760620"></a>Gupta AK, Parker BM. Bleeding ater a single dose of ketorolac in a postoperative patient. <i>Cureus</i>. 2020;12(6):e8919. doi:10.7759/cureus.8919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32760620/pubmed" id="32760620" target="_blank">32760620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30822800">
<a name="30822800"></a>Hadley EE, Monsivais L, Pacheco L, et al. Multimodal pain management for cesarean delivery: a double-blinded, placebo-controlled, randomized clinical trial. <i>Am J</i>
<i> Perinatol</i>. 2019;36(11):1097-1105. doi:10.1055/s-0039-1681096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30822800/pubmed" id="30822800" target="_blank">30822800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34553259">
<a name="34553259"></a>Hall ST, Mangram AJ, Barletta JF. Identification of risk factors for acute kidney injury from intravenous ketorolac in geriatric trauma patients. <i>World J Surg</i>. 2022;46(1):98-103. doi:10.1007/s00268-021-06320-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/34553259/pubmed" id="34553259" target="_blank">34553259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7942813">
<a name="7942813"></a>Haragsim L, Dalal R, Bagga H, Bastani B. Ketorolac-induced acute renal failure and hyperkalemia: report of three cases. <i>Am J Kidney Dis</i>. 1994;24(4):578-580. doi:10.1016/s0272-6386(12)80215-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/7942813/pubmed" id="7942813" target="_blank">7942813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8115903">
<a name="8115903"></a>Hebert WG, Scopelitis E. Ketorolac-precipitated asthma. <i>South Med J</i>. 1994;87(2):282-283. doi:10.1097/00007611-199402000-00030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8115903/pubmed" id="8115903" target="_blank">8115903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063. Erratum in: <i>Circulation</i>. 2022;145(18):e1033. Erratum in: <i>Circulation</i>. 2022;146(13):e185. Erratum in: <i>Circulation</i>. 2023;147(14):e674.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9385304">
<a name="9385304"></a>Hennessy S, Kinman JL, Berlin JA, et al. Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. <i>Arch Intern Med</i>. 1997;157(21):2510-2514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9385304/pubmed" id="9385304" target="_blank">9385304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30317488">
<a name="30317488"></a>Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. <i>Obes Surg</i>. 2019;29(2):394-400. doi: 10.1007/s11695-018-3526-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30317488/pubmed" id="30317488" target="_blank">30317488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18193919">
<a name="18193919"></a>Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/18193919/pubmed" id="18193919" target="_blank">18193919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27580638">
<a name="27580638"></a>Howard ML, Isaacs AN, Nisly SA. Continuous infusion nonsteroidal anti-inflammatory drugs for perioperative pain management. <i>J Pharm Pract</i>. 2018;31(1):66-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/27580638/pubmed" id="27580638" target="_blank">27580638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28970395">
<a name="28970395"></a>Howard ML, Warhurst RD, Sheehan C. Safety of continuous infusion ketorolac in postoperative coronary artery bypass graft surgery patients. <i>Pharmacy (Basel)</i>. 2016;4(3):22. doi:10.3390/pharmacy4030022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28970395/pubmed" id="28970395" target="_blank">28970395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30232741">
<a name="30232741"></a>Huang SP, Wen YC, Huang ST, Lin CW, Wang TD, Hsiao FY. Nonsteroidal anti-inflammatory drugs and risk of first hospitalization for heart failure in patients with no history of heart failure: A population-based case-crossover study. <i>Drug Saf</i>. 2019;42(1):67-75. doi:10.1007/s40264-018-0720-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30232741/pubmed" id="30232741" target="_blank">30232741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15754275">
<a name="15754275"></a>Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>Am J Kidney Dis</i>. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/15754275/pubmed" id="15754275" target="_blank">15754275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32393370">
<a name="32393370"></a>Javaherforooshzadeh F, Abdalbeygi H, Janatmakan F, Gholizadeh B. Comparing the effects of ketorolac and <i>Paracetamol</i> on postoperative pain relief after coronary artery bypass graft surgery. A randomized clinical trial. <i>J Cardiothorac Surg</i>. 2020;15(1):80. doi:10.1186/s13019-020-01125-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32393370/pubmed" id="32393370" target="_blank">32393370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12358284">
<a name="12358284"></a>Javier Rodríguez-González F, Montero JL, Puente J, et al. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. <i>Am J Gastroenterol</i>. 2002;97(9):2476-2477. doi:10.1111/j.1572-0241.2002.06015.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/12358284/pubmed" id="12358284" target="_blank">12358284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8797556">
<a name="8797556"></a>Judkins JH, Dray TG, Hubbell RN. Intraoperative ketorolac and posttonsillectomy bleeding. <i>Arch Otolaryngol Head Neck Surg</i>. 1996;122(9):937-940. doi:10.1001/archotol.1996.01890210017004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8797556/pubmed" id="8797556" target="_blank">8797556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2724096">
<a name="2724096"></a>Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. <i>J Pharm Sci</i>. 1989;78(4):324-327. doi:10.1002/jps.2600780413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/2724096/pubmed" id="2724096" target="_blank">2724096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Ketorolac tromethamine injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Ketorolac tromethamine injection, USP [prescribing information]. Bedminster, NJ: Alembic Pharmaceutical Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Juno.1">
<a name="Juno.1"></a>Ketorolac tromethamine injection, USP [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alvogen.1">
<a name="Alvogen.1"></a>Ketorolac tromethamine injection [prescribing information]. Pine Brook, NJ: Alvogen, Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ketorolac.5">
<a name="Ketorolac.5"></a>Ketorolac tromethamine injection [prescribing information] Prefilled Syringe. Lake Zurich, IL: Fresenius Kabi; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Ketorolac tromethamine oral [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burel.1">
<a name="Burel.1"></a>Ketorolac tromethamine tablet [prescribing information]. Mason, OH: Burel Pharmaceuticals; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int</i>. 2013;3(suppl):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37004573">
<a name="37004573"></a>Kim DH, Jeon YT, Kim HG, et al. Comparison between ketorolac- and fentanyl-based patient-controlled analgesia for acute kidney injury after robot-assisted radical prostatectomy: a retrospective propensity score-matched analysis. <i>World J Urol</i>. 2023;41(5):1437-1444. doi:10.1007/s00345-023-04374-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/37004573/pubmed" id="37004573" target="_blank">37004573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587953">
<a name="24587953"></a>Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24587953/pubmed" id="24587953" target="_blank">24587953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23175926">
<a name="23175926"></a>Klein M, Støckel M, Rosenberg J, Gögenur I. Intraoperative ketorolac and bleeding after laparoscopic Roux-en-Y gastric by-pass surgery. <i>Acta Chir Belg</i>. 2012;112(5):369-373. doi:10.1080/00015458.2012.11680854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23175926/pubmed" id="23175926" target="_blank">23175926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17609236">
<a name="17609236"></a>Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. <i>Ann Pharmacother</i>. 2007;41(7):1191-1200. doi:10.1345/aph.1K023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/17609236/pubmed" id="17609236" target="_blank">17609236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280110">
<a name="24280110"></a>Kohli P, Steg PG, Cannon CP, et al; REACH Registry Investigators. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. <i>Am J Med</i>. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24280110/pubmed" id="24280110" target="_blank">24280110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30216468">
<a name="30216468"></a>Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. <i>Allergy</i>. 2019;74(1):28-39. doi:10.1111/all.13599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30216468/pubmed" id="30216468" target="_blank">30216468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117484">
<a name="24117484"></a>Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Allergy</i>. 2013;68(10):1219-1232. doi:10.1111/all.12260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24117484/pubmed" id="24117484" target="_blank">24117484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749768">
<a name="25749768"></a>Kowalski ML, Makowska JS. Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? <i>Allergy Asthma Immunol Res</i>. 2015;7(4):312-320. doi:10.4168/aair.2015.7.4.312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25749768/pubmed" id="25749768" target="_blank">25749768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21631520">
<a name="21631520"></a>Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. <i>Allergy</i>. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/21631520/pubmed" id="21631520" target="_blank">21631520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27968707">
<a name="27968707"></a>Kulo A, Smits A, Maleškić S, Van de Velde M, Van Calsteren K, De Hoon J, Verbesselt R, Deprest J, Allegaert K. Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. <i>Bosn J Basic Med Sci</i>. 2017;17(1):54-60. doi:10.17305/bjbms.2016.1515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/27968707/pubmed" id="27968707" target="_blank">27968707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900801">
<a name="12900801"></a>Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. <i>Am J Kidney Dis</i>. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/12900801/pubmed" id="12900801" target="_blank">12900801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28483309">
<a name="28483309"></a>Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):537-545. doi:10.1016/j.jaip.2016.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28483309/pubmed" id="28483309" target="_blank">28483309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20955443">
<a name="20955443"></a>Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.<i> Aliment Pharmacol Ther</i>. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/20955443/pubmed" id="20955443" target="_blank">20955443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25402512">
<a name="25402512"></a>Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. <i>Ann Intern Med</i>. 2014;161(10):690-698. doi:10.7326/M13-1581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25402512/pubmed" id="25402512" target="_blank">25402512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299844">
<a name="23299844"></a>Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. doi:10.1136/bmj.e8525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23299844/pubmed" id="23299844" target="_blank">23299844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36892424">
<a name="36892424"></a>Lee J, Zhou EP, Davis RL, Ouyang Y, Lin HM, Yudkowitz FS. Bleeding and ketorolac use in pediatric circumcision. <i>Paediatr Anaesth</i>. 2023;33(6):481-485. doi:10.1111/pan.14661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/36892424/pubmed" id="36892424" target="_blank">36892424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17456651">
<a name="17456651"></a>Lynn AM, Bradford H, Kantor ED, et al, "Postoperative Ketorolac Tromethamine Use in Infants Aged 6-18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics," <i>Anesth Analg</i>, 2007, 104(5):1040-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/17456651/pubmed" id="17456651" target="_blank">17456651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8520083">
<a name="8520083"></a>Maliekal J, Elboim CM. Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. <i>Ann Pharmacother</i>. 1995;29(7-8):698-701. doi:10.1177/106002809502907-808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8520083/pubmed" id="8520083" target="_blank">8520083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29075132">
<a name="29075132"></a>Mariano F, Cogno C, Giaretta F, et al. Urinary protein profiles in ketorolac-associated acute kidney injury in patients undergoing orthopedic day surgery. <i>Int J Nephrol Renovasc Dis</i>. 2017;10:269-274. doi:10.2147/IJNRD.S137102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29075132/pubmed" id="29075132" target="_blank">29075132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266539">
<a name="29266539"></a>McLay JS, Engelhardt T, Mohammed BS, et al. The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. <i>Paediatr Anaesth</i>. 2018;28(2):80-86. doi:10.1111/pan.13302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29266539/pubmed" id="29266539" target="_blank">29266539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9754982">
<a name="9754982"></a>Menniti-Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. <i>Eur J Clin Pharmacol</i>. 1998;54(5):393-397. doi:10.1007/s002280050481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9754982/pubmed" id="9754982" target="_blank">9754982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21618455">
<a name="21618455"></a>Micu MC, Micu R, Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. <i>Arthritis Care Res (Hoboken)</i>. 2011;63(9):1334-1338. doi:10.1002/acr.20510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/21618455/pubmed" id="21618455" target="_blank">21618455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3547002">
<a name="3547002"></a>Miescher PA. Blood dyscrasias secondary to non-steroidal anti-inflammatory drugs. <i>Med Toxicol</i>. 1986;1 Suppl 1:57-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3547002/pubmed" id="3547002" target="_blank">3547002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36757490">
<a name="36757490"></a>Minaldi E, Cahill K. Recent updates in understanding NSAID hypersensitivity. <i>Curr Allergy Asthma Rep</i>. 2023;23(3):181-188. doi:10.1007/s11882-023-01064-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/36757490/pubmed" id="36757490" target="_blank">36757490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23360563">
<a name="23360563"></a>Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. <i>J Pediatr</i>. 2013;162(6):1153-1159, 1159.e1. doi:10.1016/j.jpeds.2012.11.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23360563/pubmed" id="23360563" target="_blank">23360563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23088994">
<a name="23088994"></a>Moffett BS, Cabrera A. Ketorolac-associated renal morbidity: risk factors in cardiac surgical infants. <i>Cardiol Young</i>. 2013;23(5):752-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23088994/pubmed" id="23088994" target="_blank">23088994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16618297">
<a name="16618297"></a>Moffett BS, Wann TI, Carberry KE, et al, "Safety of Ketorolac in Neonates and Infants After Cardiac Surgery," <i>Paediatr Anaesth</i>, 2006, 16(4):424-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/16618297/pubmed" id="16618297" target="_blank">16618297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 2, 2014. www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9422305">
<a name="9422305"></a>Niemi TT, Taxell C, Rosenberg PH. Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers.<i> Acta Anaesthesiol Scand</i>. 1997;41(10):1353-1358. doi:10.1111/j.1399-6576.1997.tb04657.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/9422305/pubmed" id="9422305" target="_blank">9422305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959716">
<a name="27959716"></a>Nissen SE, Yeomans ND, Solomon DH, et al; PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. <i>N Engl J Med</i>. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/27959716/pubmed" id="27959716" target="_blank">27959716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3045551">
<a name="3045551"></a>Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). <i>N Engl J Med</i>. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3045551/pubmed" id="3045551" target="_blank">3045551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24231193">
<a name="24231193"></a>Oliveri L, Jerzewski K, Kulik A. Black box warning: is ketorolac safe for use after cardiac surgery? <i>J Cardiothorac Vasc Anesth</i>. 2014;28(2):274-279. doi:10.1053/j.jvca.2013.07.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/24231193/pubmed" id="24231193" target="_blank">24231193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28052268">
<a name="28052268"></a>Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. <i>Digestion</i>. 2017;95(1):22-28. doi:10.1159/000452356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28052268/pubmed" id="28052268" target="_blank">28052268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426. Erratum in: <i>Circulation</i>. 2016;134(12):e261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469671">
<a name="16469671"></a>Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of <i>Helicobacter pylori</i> and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. <i>Clin Gastroenterol Hepatol</i>. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/16469671/pubmed" id="16469671" target="_blank">16469671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028762">
<a name="29028762"></a>Penk JS, Lefaiver CA, Brady CM, Steffensen CM, Wittmayer K. Intermittent versus continuous and intermittent medications for pain and sedation after pediatric cardiothoracic surgery; a randomized controlled trial. <i>Crit Care Med</i>. 2018;46(1):123-129. doi:10.1097/CCM.0000000000002771<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29028762/pubmed" id="29028762" target="_blank">29028762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012355">
<a name="2012355"></a>Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. <i>Ann Intern Med</i>. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/2012355/pubmed" id="2012355" target="_blank">2012355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.2016">
<a name="APS.2016"></a>
<i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. Glenview, IL: American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8007038">
<a name="8007038"></a>Quan DJ, Kayser SR. Ketorolac induced acute renal failure following a single dose. <i>J Toxicol Clin Toxicol</i>. 1994;32(3):305-309. doi:10.3109/15563659409017963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8007038/pubmed" id="8007038" target="_blank">8007038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439535">
<a name="25439535"></a>Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. <i>Prim Care</i>. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25439535/pubmed" id="25439535" target="_blank">25439535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443483">
<a name="8443483"></a>Randi ML, Tison T, Luzzatto G, Girolami A. Haemolytic uraemic syndrome during treatment with ketorolac trometamol. <i>BMJ</i>. 1993;306(6871):186. doi:10.1136/bmj.306.6871.186-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8443483/pubmed" id="8443483" target="_blank">8443483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031832">
<a name="20031832"></a>Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. <i>Circ Cardiovasc Qual Outcomes</i>. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/20031832/pubmed" id="20031832" target="_blank">20031832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8010474">
<a name="8010474"></a>Ready LB, Brown CR, Stahlgren LH, et al. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain. A double-blind, placebo-controlled, multicenter study. <i>Anesthesiology</i>. 1994;80(6):1277-1286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8010474/pubmed" id="8010474" target="_blank">8010474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM Clinical Protocol #15: Analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Canada.1">
<a name="Canada.1"></a>Refer to Canadian labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877042">
<a name="10877042"></a>Reinhart DI. Minimising the adverse effects of ketorolac.<i> Drug Saf</i>. 2000;22(6):487-497. doi:10.2165/00002018-200022060-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/10877042/pubmed" id="10877042" target="_blank">10877042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11133001">
<a name="11133001"></a>RuDusky BM. Severe postoperative hemorrhage attributed to single-dose parenteral ketorolac-induced coagulopathy. <i>Angiology</i>. 2000;51(12):999-1002. doi:10.1177/000331970005101203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11133001/pubmed" id="11133001" target="_blank">11133001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020251">
<a name="29020251"></a>Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. <i>Eur Heart J</i>. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29020251/pubmed" id="29020251" target="_blank">29020251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33100559">
<a name="33100559"></a>Sahu N, Roy J, Vunnam R, Golamari R, Jain R. Naproxen-induced thrombocytopenia. <i>Proc (Bayl Univ Med Cent)</i>. 2020;33(4):653-654. doi:10.1080/08998280.2020.1798724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/33100559/pubmed" id="33100559" target="_blank">33100559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3545733">
<a name="3545733"></a>Sanford-Driscoll M, Knodel LC. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. <i>Drug Intell Clin Pharm</i>. 1986;20(12):925-934. doi:10.1177/106002808602001202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3545733/pubmed" id="3545733" target="_blank">3545733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11240963">
<a name="11240963"></a>Scala E, Giani M, Pirrotta L, et al. Selective severe anaphylactic reaction due to ketorolac tromethamine without nonsteroidal anti-inflammatory drug intolerance. <i>J Allergy Clin Immunol</i>. 2001;107(3):557. doi:10.1067/mai.2001.113241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/11240963/pubmed" id="11240963" target="_blank">11240963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19269020">
<a name="19269020"></a>Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. <i>Thromb Res</i>. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/19269020/pubmed" id="19269020" target="_blank">19269020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21555710">
<a name="21555710"></a>Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. <i>Circulation</i>. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/21555710/pubmed" id="21555710" target="_blank">21555710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710657">
<a name="25710657"></a>Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. <i>JAMA</i>. 2015;313(8):805-814. doi:10.1001/jama.2015.0809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/25710657/pubmed" id="25710657" target="_blank">25710657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26984863">
<a name="26984863"></a>Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>Eur Heart J</i>. 2016;37(13):1015-1023. doi:10.1093/eurheartj/ehv505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26984863/pubmed" id="26984863" target="_blank">26984863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17005625">
<a name="17005625"></a>Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. <i>Am J Epidemiol</i>. 2006;164(9):881-889. doi:10.1093/aje/kwj331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/17005625/pubmed" id="17005625" target="_blank">17005625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2021">
<a name="Schwedt.2021"></a>Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mariano.2020">
<a name="Mariano.2020"></a>Schwenk ES. Nonopioid pharmacotherapy for acute pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28478713">
<a name="28478713"></a>Schwinghammer AJ, Isaacs AN, Benner RW, Freeman H, O'Sullivan JA, Nisly SA. Continuous infusion ketorolac for postoperative analgesia following unilateral total knee arthroplasty. <i>Ann Pharmacother</i>. 2017;51(6):451-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28478713/pubmed" id="28478713" target="_blank">28478713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8189303">
<a name="8189303"></a>Shapiro N. Acute angioedema after ketorolac ingestion: report of case. <i>J Oral Maxillofac Surg</i>. 1994;52(6):626-627. doi:10.1016/0278-2391(94)90103-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8189303/pubmed" id="8189303" target="_blank">8189303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14523887">
<a name="14523887"></a>Singer AJ, Mynster CJ, McMahon BJ. The effect of IM ketorolac tromethamine on bleeding time: a prospective, interventional, controlled study.<i> Am J Emerg Med</i>. 2003;21(5):441-443. doi:10.1016/s0735-6757(03)00100-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/14523887/pubmed" id="14523887" target="_blank">14523887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28756267">
<a name="28756267"></a>Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: A secondary analysis of the PRECISION trial. <i>Am J Med</i>. 2017;130(12):1415-1422.e4. doi:10.1016/j.amjmed.2017.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28756267/pubmed" id="28756267" target="_blank">28756267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-276660">
<a name="276660"></a>Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. <i>N Y State J Med.</i> 1978;78(8):1239-1243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/276660/pubmed" id="276660" target="_blank">276660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26925883">
<a name="26925883"></a>Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26925883/pubmed" id="26925883" target="_blank">26925883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8569017">
<a name="8569017"></a>Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. <i>JAMA</i>. 1996;275(5):376-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8569017/pubmed" id="8569017" target="_blank">8569017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8379803">
<a name="8379803"></a>Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FE Jr. Nonsteroidal anti-inflammatory drugs and neutropenia. <i>Arch Intern Med</i>. 1993;153(18):2119-2124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8379803/pubmed" id="8379803" target="_blank">8379803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31937550">
<a name="31937550"></a>Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <i>Gut</i>. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/31937550/pubmed" id="31937550" target="_blank">31937550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298250">
<a name="23298250"></a>Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. <i>Headache</i>. 2013;53(2):277-287. doi:10.1111/head.12009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23298250/pubmed" id="23298250" target="_blank">23298250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31669738">
<a name="31669738"></a>Teigen NC, Sahasrabudhe N, Doulaveris G, et al. Enhanced recovery after surgery at cesarean delivery to reduce postoperative length of stay: A randomized controlled trial. <i>Am J Obstet </i>
<i>Gynecol</i>. 2020;222(4):372.e1–372.e10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/31669738/pubmed" id="31669738" target="_blank">31669738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943657">
<a name="26943657"></a>Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. <i>World J Surg</i>. 2016;40(9):2065-2083. doi: 10.1007/s00268-016-3492-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26943657/pubmed" id="26943657" target="_blank">26943657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Toradol.1">
<a name="Toradol.1"></a>Toradol (ketorolac) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Toradol.2">
<a name="Toradol.2"></a>Toradol IM (ketorolac) [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic</a>. Published October 15, 2020. Accessed October 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28429492">
<a name="28429492"></a>Välitalo PA, Kemppainen H, Kulo A, et al. Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. <i>Br J Clin Pharmacol</i>. 2017;83(9):1966-1975.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/28429492/pubmed" id="28429492" target="_blank">28429492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1321554">
<a name="1321554"></a>Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. <i>Agents Actions Suppl</i>. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/1321554/pubmed" id="1321554" target="_blank">1321554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3264528">
<a name="3264528"></a>Walker JJ, Johnstone J, Lloyd J, et al, "Transfer of Ketorolac Tromethamine From Maternal to Foetal Blood," <i>Eur J Clin Pharmacol</i>, 1988, 34(5):509-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/3264528/pubmed" id="3264528" target="_blank">3264528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10377455">
<a name="10377455"></a>Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. <i>Proc Natl Acad Sci U S A</i>. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563. Erratum in: <i>Proc Natl Acad Sci U S A.</i> 1999;96(17):9666<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/10377455/pubmed" id="10377455" target="_blank">10377455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26377377">
<a name="26377377"></a>Warth LC, Noiseux NO, Hogue MH, Klaassen AL, Liu SS, Callaghan JJ. Risk of acute kidney injury after primary and revision total hip arthroplasty and total knee arthroplasty using a multimodal approach to perioperative pain control including ketorolac and celecoxib. <i>J Arthroplasty</i>. 2016;31(1):253-255. doi:10.1016/j.arth.2015.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/26377377/pubmed" id="26377377" target="_blank">26377377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1394752">
<a name="1394752"></a>Watcha MF, Ramirez-Ruiz M, White PF, Jones MB, Lagueruela RG, Terkonda RP. Perioperative effects of oral ketorolac and acetaminophen in children undergoing bilateral myringotomy. <i>Can J Anaesth</i>. 1992;39(7):649-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/1394752/pubmed" id="1394752" target="_blank">1394752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390124">
<a name="10390124"></a>Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i>. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/10390124/pubmed" id="10390124" target="_blank">10390124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207919">
<a name="30207919"></a>White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. <i>N Engl J Med</i>. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/30207919/pubmed" id="30207919" target="_blank">30207919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2787750">
<a name="2787750"></a>Wischnik A, Manth SM, Lloyd J, et al, "The Excretion of Ketorolac Tromethamine Into Breast Milk After Multiple Oral Dosing," <i>Eur J Clin Pharmacol</i>, 1989, 36(5):521-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/2787750/pubmed" id="2787750" target="_blank">2787750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8782036">
<a name="8782036"></a>Witting MD. Renal papillary necrosis following emergency department treatment of migraine. <i>J Emerg Med</i>. 1996;14(3):373-376. doi:10.1016/0736-4679(96)00036-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/8782036/pubmed" id="8782036" target="_blank">8782036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23747642">
<a name="23747642"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/23747642/pubmed" id="23747642" target="_blank">23747642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667211">
<a name="29667211"></a>Yeomans ND, Graham DY, Husni ME, et al; PRECISION investigators. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. <i>Aliment Pharmacol Ther</i>. 2018;47(11):1453-1463. doi:10.1111/apt.14610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/29667211/pubmed" id="29667211" target="_blank">29667211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259118">
<a name="32259118"></a>Yousefi H, Sahebi A, Farahani M, Golitaleb M. Anaphylaxis as a rare side effect of ketorolac; a case report. <i>Arch Acad Emerg Med</i>. 2020;8(1):e22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32259118/pubmed" id="32259118" target="_blank">32259118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32947103">
<a name="32947103"></a>Yurashevich M, Pedro C, Fuller M, Habib AS. Intra-operative ketorolac 15 mg versus 30 mg for analgesia following cesarean delivery: a retrospective study. <i>Int J Obstet Anesth</i>. 2020;44:116-121. doi:10.1016/j.ijoa.2020.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/32947103/pubmed" id="32947103" target="_blank">32947103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-447795">
<a name="447795"></a>Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. <i>J Clin Endocrinol Metab</i>. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/447795/pubmed" id="447795" target="_blank">447795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31984540">
<a name="31984540"></a>Zoubek ME, Lucena MI, Andrade RJ, Stephens C. Systematic review: ibuprofen-induced liver injury. <i>Aliment Pharmacol Ther</i>. 2020;51(6):603-611. doi:10.1111/apt.15645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-systemic-pediatric-drug-information/abstract-text/31984540/pubmed" id="31984540" target="_blank">31984540</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16007 Version 589.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
